



One Evertrust Plaza, Suite 1207  
Jersey City, NJ, 07302  
Phone: 201-401-1104  
Email: celltrionusa@celltrion.com

October 25, 2019

**NOTIFICATION PURSUANT TO  
18 V.S.A. § 4637(b)**

**Subject:** Notification of a new prescription drug

**To:** The Office of the Attorney General of Vermont

Celltrion USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug pursuant to 18 V.S.A. § 4637(b).

<b>Name of New Prescription Drug</b>	<b>NDC Number</b>	<b>Date of Commercial Availability</b>	<b>Wholesale Acquisition Cost as of the date of Commercial Availability</b>
TEMIXYS™ (lamivudine and tenofovir disoproxil fumarate)	72606-0002-01	09/30/2019	\$850

Celltrion USA, Inc. became aware of this reporting requirement after the launch of this product and is aware that an additional 30 day report is due and is currently working on compiling the required information.

Sincerely,

  
BonJoong Kim  
CEO